mouse bone marrow macrophages

mouse bone marrow macrophages

Cat.No.: CSC-C1940

Species: Mouse

Source: Bone Marrow

Cell Type: Macrophage

  • Specification
  • Background
  • Scientific Data
  • Q & A
  • Customer Review
Cat.No.
CSC-C1940
Description
Mouse Bone Marrow Macrophages are derived from the tibias and femurs of pathogen-free laboratory adult mice. Mouse Bone Marrow Macrophages are grown in 100 mm treated tissue culture dish and incubated in Creative Bioarray Culture Medium for 7-10 days. Each vial contains at least 6x10^6 cells. Mouse Bone Marrow Macrophages are negative for bacteria, yeast, fungi, and mycoplasma. Cells can be expanded on a multiwell culture plate ready for experiments under the cell culture conditions specified by Creative Bioarray. Repeated freezing and thawing of cells is not recommended.
Species
Mouse
Source
Bone Marrow
Recommended Medium
HighQua Macrophage Medium Kit
Cell Type
Macrophage
Disease
Normal
Storage and Shipping
ship in dry ice; store in liquid nitrogen
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

Bone marrow macrophages (BMMs) are primary macrophages isolated from the bone marrow of long bones in mice, such as the femur and tibia. Hematopoietic progenitor cells can be extracted from bone marrow and differentiated ex vivo to produce mature macrophages under continuous stimulation with macrophage colony-stimulating factor (M-CSF). As such, BMMs are a pure and physiologically relevant population that recapitulates the innate immune functions of macrophages in vivo.

BMMs adhere and have a polygonal or elongated shape with extensive cytoplasmic projections typical for professional phagocytes. They express well-known macrophage markers such as F4/80, CD11b, CD68, and MHC-II and are highly phagocytic with robust cytokine responses. BMMs can be polarized toward M1 (pro-inflammatory) or M2 (anti-inflammatory) phenotypes upon stimulation, making them a flexible tool to study macrophage biology and inflammatory signaling pathways. Functionally, BMMs play central roles in antigen processing, microbial clearance, ROS/NO production, and modulation of inflammatory cytokine networks. BMMs have been used to model host-pathogen interactions, innate immune activation, chronic inflammatory diseases, metabolic conditions, and autoimmune disorders due to their physiological relevance and reproducibility.

Photomicrographs of primary cultures of mouse monocytes/macrophages at selected incubation times in vitro.

Fig. 1. Photomicrographs of primary cultures of mouse monocytes/macrophages at selected incubation times in vitro (Zeng L B, Yang S M, et al., 2006).

Prmt1-mediated methylation regulates Ncoa4 stability to transactivate Adamts genes and promote bone extracellular matrix degradation in chronic hematogenous osteomyelitis

Biology Direct | DOI | Paper |

Background

This study investigates how protein arginine methyltransferases contribute to chronic hematogenous osteomyelitis (CHOM). Using a Staphylococcus aureus-infected mouse model, the authors show that Prmt1 is uniquely upregulated in osteoblasts and osteocytes. Prmt1 methylates Ncoa4 at R242, stabilizing it and enabling formation of an Ncoa4-Cbp-Ap1 transcriptional complex that activates Adamts3/8/12/14. These proteases promote bone extracellular matrix degradation and bone destruction. Prmt1 inhibitors TCE-5003 and MS023 reduce Ncoa4 methylation, induce Rnf8-mediated Ncoa4 ubiquitination/degradation, suppress Adamts expression, and mitigate osteomyelitis progression, identifying Prmt1 as a therapeutic target.

Key Findings

Among nine Prmt family members, Prmt1 was the only one significantly upregulated in S. aureus-induced CHOM mice and in IL-1β/TNF-α-treated osteoblasts and osteocytes, but not osteoclasts or macrophages. Prmt1 directly interacted with and methylated Ncoa4 at R242, enhancing Ncoa4 stability. Methylated Ncoa4 assembled with Cbp and Ap1 (c-Jun/c-Fos) and bound to promoters of Adamts3, Adamts8, Adamts12, and Adamts14, driving their transcription and promoting bone ECM degradation. Prmt1 depletion or inhibition prevented Ncoa4 methylation, leading to Rnf8-mediated ubiquitination at K49 and proteasomal degradation, thereby downregulating Adamts expression. In vivo, TCE-5003 and MS023 reduced bone destruction, bacterial load, and CHOM progression, supporting Prmt1 as a therapeutic target.

Contribution

Creative Bioarray provided two key cell lines: MOCY-1 osteocytes (#CSC-C5334S) and MBMM-1 bone marrow macrophages (#CSC-C1940). These enabled the authors to test Prmt1 expression across bone cell types and demonstrate that inflammatory cytokines specifically upregulate Prmt1 in osteoblasts/osteocytes, supporting the cell-type-specific mechanism.

Schematic models of the Prmt1/Ncoa4-Cbp-Ap1/Adamts signaling axis in CHOM pathogenesis and its therapeutic inhibition.
Fig. 1. Schematic models of the Prmt1/Ncoa4-Cbp-Ap1/Adamts signaling axis in CHOM pathogenesis and its therapeutic inhibition.

Role of NLRP3 Inflammasome and IL-1β in Osteoclastogenesis in the Presence and Absence of Lipopolysaccharide (LPS)

The NLRP3 inflammasome is known to promote bone resorption during inflammatory bone diseases like periodontitis by inducing the production of IL-1β. The NLRP3 inflammasome's role in physiological bone remodeling however remains to be determined. Alam et al. investigated the role of the NLRP3 inflammasome in osteoclastogenesis in the presence and absence of LPS.

To explore if the NLRP3 inflammasome regulates RANKL-induced osteoclast formation, Alam et al. measured NLRP3 components and IL-1β in mouse bone marrow macrophages (BMMs) treated with RANKL ± LPS. RANKL induced osteoclastogenesis in a dose-dependent manner with M-CSF (Fig. 1a). Treatment with RANKL + LPS increased the number of osteoclasts (Fig. 1b). Treatment with RANKL alone, but not LPS, upregulated Nlrp3 and Caspase-1 mRNA expression but not Asc or Il-1β (Fig. 1c) and increased NLRP3 and cleaved caspase-1 protein (Fig. 1d). With RANKL + LPS, all components (Nlrp3, Caspase-1, and Il-1β) were upregulated while Asc was downregulated. From these data, it can be concluded that RANKL is able to upregulate Nlrp3 and Caspase-1 but not Il-1β without LPS. Next, they analyzed whether IL-1β plays a role in BMMs. RANKL alone did not induce IL-1β in the supernatant or lysate (Fig. 2a). In the presence of LPS, IL-1β was detected in the lysate but not the supernatant (Fig. 2b). Alam et al. then tested the effect of recombinant IL-1 receptor antagonist (rIL-1ra) and determined that it did not affect osteoclast formation without LPS (Fig. 2c) while inhibiting it with LPS (Fig. 2d). These data suggests that IL-1β is required for osteoclastogenesis in the presence of LPS but not in its absence.

NLRP3 inflammasome-related gene and protein expression in bone marrow macrophages (BMMs) treated with receptor activator of nuclear factor-κB ligand (RANKL) in the presence or absence of lipopolysaccharide (LPS).

Fig. 2. NLRP3 inflammasome-related gene and protein expression in bone marrow macrophages (BMMs) treated with receptor activator of nuclear factor-κB ligand (RANKL) in the presence or absence of lipopolysaccharide (LPS) (Alam MI, Mae M, et al., 2022).

Production of IL-1β and its involvement in osteoclastogenesis.

Fig. 3. Production of IL-1β and its involvement in osteoclastogenesis (Alam MI, Mae M, et al., 2022).

Ask a Question

Write your own review

For research use only. Not for any other purpose.

Hot Products